CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

Precision medicine is an integrative approach to cardiovascular disease prevention and
treatment that considers an individual's genetics, lifestyle, and exposures as determinants of …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …

The standing guideline writing committee along with the parent Task Force identified trials
and other key data through October 2011 that may impact guideline recommendations. On …

Since September 2010, more than 10,000 patients have undergone preemptive, panel‐
based pharmacogenomic testing through the Vanderbilt Pharmacogenomic Resource for …

The cardiovascular research and clinical communities are ideally positioned to address the
epidemic of noncommunicable causes of death, as well as advance our understanding of …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …